References
1. Kaiser J, Couzin-Frankel J. BIOMEDICAL RESEARCH. Biden seeks clear
course for his cancer moonshot. Science 2016;351:325-6.
2. Singer DS, Jacks T, Jaffee E. A U.S. “Cancer Moonshot” to
accelerate cancer research. Science 2016;353:1105-6.
3. Yaffe MB, VanHook AM. Science Signaling Podcast for 14 March
2017: The Cancer Moonshot. Sci Signal 2017;10:eaan1418.
4. Hu CS, Tkebuchava T. SEEDi1.0-3.0 strategies for
major noncommunicable diseases in
China. J Integr Med 2017;15:265-9.
5. Chen W, et al. Cancer statistics in China, 2015. CA Cancer J Clin
2016;66:115-32.
6. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA
Cancer J Clin 2022;72:7-33.
7. Islami F, et al. American Cancer Society’s report on the status of
cancer disparities in the United States, 2021. CA Cancer J Clin
2022;72:112-43.
8. Spicer J, Chamberlain C, Papa S. Provision of cancer care during
the COVID-19 pandemic. Nat Rev Clin Oncol 2020;17:329-31.
9. Sengar M, et al. TMH COVID-19 action group. Outcomes of COVID-19 and
risk factors in patients with cancer. Nat Cancer 2022; Apr 4.
10. van de Haar J, et al. Caring for patients with cancer in
the COVID-19 era. Nat Med 2020;26(5):665-671.
11. van der Veldt AAM, et al. COVID-19 vaccination: the VOICE for
patients with cancer. Nat Med 2021;27(4):568-569.
12. Hofman P, Puchois P, Brest P, Lahlou H, Simeon-Dubach D. Possible
consequences of the COVID-19 pandemic on the use of biospecimens
from cancer biobanks for research in academia and bioindustry. Nat Med
2020;26(6):809-810.
13. Fendler A, et al. COVID-19 vaccines in patients with cancer:
immunogenicity, efficacy and safety. Nat Rev Clin Oncol 2022;..:1-17.
14. Bisceglia I, et al. Cardio-Oncology in the COVID Era (Co & Co): The
Never Ending Story. Front Cardiovasc Med 2022;9:821193.
15. Huang Y, et al. Clinical characteristics, risk factors, and cardiac
manifestations of cancer patients with COVID-19. J Appl Physiol (1985)
2021;131:966-76.
16. Lee LY, et al. UK Coronavirus Monitoring Project Team, Kerr R,
Middleton G. COVID-19 mortality in patients with cancer on chemotherapy
or other anticancer treatments: a prospective cohort study. Lancet
2020;395:1919-26.
17. Drozd M, et al. Non-communicable disease, sociodemographic factors,
and risk of death from infection: a UK Biobank observational cohort
study. Lancet Infect Dis 2021;21:1184-91.
18. Lenihan D, et al. Cardio-oncology care in the era of
the coronavirus disease 2019 (COVID-19) pandemic: An International
Cardio-Oncology Society (ICOS) statement. CA Cancer J Clin
2020;70:480-504.
19. Katsoularis I, Fonseca-Rodríguez O, Farrington P, Lindmark K, Fors
Connolly AM. Risk of acute myocardial infarction and ischaemic stroke
following COVID-19 in Sweden: a self-controlled case series and matched
cohort study. Lancet 2021;398:599-607.
20. Giaquinto AN, Miller KD, Tossas KY, Winn RA, Jemal A, Siegel RL.
Cancer statistics for African American/Black People 2022. CA Cancer J
Clin 2022; 72(3):202-229.
21. Miller KD, et al. Cancer treatment and survivorship statistics,
2019. CA Cancer J Clin 2019;69:363-385.
22. Goshua G, et al. Endotheliopathy in COVID-19-associated
coagulopathy: evidence from a single-centre, cross-sectional study.
Lancet Haematol 2020;7:e575-82.
23. Delorey TM, et al. COVID-19 tissue atlases
reveal SARS-CoV-2 pathology and cellular targets. Nature
2021;595:107-13.
24. Wei J, et al. Genome-wide CRISPR Screens Reveal Host Factors
Critical for SARS-CoV-2 Infection. Cell 2021;184:76-91.e13.
25. Kutikov A, Weinberg DS, Edelman MJ, Horwitz EM, Uzzo RG, Fisher RI.
A War on Two Fronts: Cancer Care in the Time of COVID-19. Ann Intern Med
2020;172:756-8.
26. Barnabas RV, Wald A. A Public Health COVID-19 Vaccination Strategy
to Maximize the Health Gains for Every Single Vaccine Dose. Ann Intern
Med 2021;174:552-3.
27. Gottlieb RL, et al. GS-US-540-9012 (PINETREE) Investigators. Early
Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N
Engl J Med 2022;386:305-15.
28. Patel K, et al. Use of the IL-6R antagonist tocilizumab in
hospitalized COVID-19 patients. J Intern Med 2021;289:430-3.
29. Sadoff J, et al. ENSEMBLE Study Group. Safety and Efficacy of
Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med
2021;384:2187-201.
30. Sadoff J, et al. ENSEMBLE Study Group. Final Analysis of Efficacy
and Safety of Single-Dose Ad26.COV2.S. N Engl J Med 2022;386:847-60.
31. Baden LR, et al. COVE Study Group. Efficacy and Safety of the
mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384:403-16.
32. El Sahly HM, et al. COVE Study Group. Efficacy of the
mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J
Med 2021;385:1774-85.
33. O’Brien MP, et al. Covid-19 Phase 3 Prevention Trial Team.
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. N Engl
J Med 2021;385:1184-95.
34. Gupta A, et al. COMET-ICE Investigators. Early Treatment
for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J
Med 2021;385:1941-50.
35. ACTIV-3/TICO Bamlanivimab Study Group, Lundgren JD, et al. Responses
to a Neutralizing Monoclonal Antibody for
Hospitalized Patients With COVID-19 According to Baseline Antibody and
Antigen Levels : A Randomized Controlled Trial. Ann Intern Med
2022;175:234-43.
36. Patone M, et al. Risks of myocarditis, pericarditis, and cardiac
arrhythmias associated with COVID-19 vaccination
or SARS-CoV-2 infection. Nat Med 2022;28(2):410-422.
37. Au L, et al. Crick COVID-19 Consortium, Swanton C, Fribbens C,
Wilkinson KA, Wilkinson RJ, Lau DK, Banerjee S, Starling N, Chau I;
CAPTURE Consortium, Turajlic S. Cytokine release syndrome in a patient
with colorectal cancer after vaccination with BNT162b2. Nat Med
2021;27(8):1362-1366.
38. Shroff RT, et al. A third dose of BNT162b2 (mRNA vaccine of
COVID-19) is safe, improves humoral immunity against SARS-CoV-2 and
could be immunologically beneficial for patients with cancer (solid
tumors) on active chemotherapy. Immune responses to two and three doses
of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med
2021;27(11):2002-2011.
39. Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation
of COVID-19 Mortality and Adverse Outcomes in US Patients With or
Without Cancer. JAMA Oncol. 2022;8(1):69-78.
40. Wang W, Kaelber DC, Xu R, Berger NA.
Breakthrough SARS-CoV-2 Infections, ospitalizations, and Mortality in
Vaccinated Patients With Cancer in the US Between December 2020 and
November 2021. JAMA Oncol. 2022; Apr 8.
doi: 10.1001/jamaoncol.2022.1096.
41. Katsoularis I, et al. Risks of deep vein thrombosis, pulmonary
embolism, and bleeding after covid-19: nationwide self-controlled cases
series and matched cohort study. BMJ. 2022;377:e069590.
42. Wu JT, et al. Association of COVID-19 Vaccination
With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide
Veterans Affairs Study. JAMA Oncol. 2022;8(2):281-286.
43. Giuliano AR, et al. Evaluation of Antibody Response
to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.
JAMA Oncol. 2022:e220001.
44. Hawley JE, et al. COVID-19 and Cancer Consortium (CCC19). Assessment
of Regional Variability in COVID-19 Outcomes Among Patients
With Cancer in the United States. JAMA Netw Open. 2022;5(1):e2142046.
45. Fenioux C, et al. SARS-CoV-2 Antibody Response to 2 or 3 Doses of
the BNT162b2 Vaccine in Patients Treated With Anticancer Agents.
JAMA Oncol. 2022;8(4):612-617.
46. Khan QJ, et al. Evaluation of the Durability of the Immune Humoral
Response to COVID-19 Vaccines in Patients With Cancer Undergoing
Treatment or Who Received a Stem Cell Transplant. JAMA Oncol. 2022;
doi: 10.1001/jamaoncol.2022.0752.
47. Obeid M, et al. Humoral Responses Against Variants of Concern
by COVID-19 mRNA Vaccines in Immunocompromised Patients. JAMA Oncol.
2022:e220446.
48. Mair MJ, et al. Third dose of SARS-CoV-2 vaccination in
hemato-oncological patients and health care workers: immune responses
and adverse events - a retrospective cohort study. Eur J Cancer.
2022;165:184-194.
49. OnCovid Study Group, Pinato DJ, et al.
Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated
Analysis of the OnCovid Registry. JAMA Oncol. 2022;8(1):114-122.
50. Scoccianti S, Delli Paoli C, Grilli Leonulli B, et al.
Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in
patients with cancer treated with radiotherapy. Lancet Oncol.
2021;22(9):1212-1214.
51. Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, et al.
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy,
immunotherapy, or chemoimmunotherapy for solid tumours: a prospective,
multicentre, non-inferiority trial. Lancet Oncol. 2021;22(12):1681-1691.
52. Morris VK, Kopetz S. Don’t blame the messenger: lessons learned
for cancer mRNA vaccines during the COVID-19 pandemic. Nat Rev Cancer.
2022 Mar 11:1-2. doi: 10.1038/s41568-022-00463-4.
53. Levine RL, Rathmell WK. COVID-19 impact on early career
investigators: a call for action. Nat Rev Cancer. 2020;20(7):357-358.
54. Mulholland EJ. Impact of COVID-19 on in vivo work and patient sample
availability for cancer research. Nat Rev Cancer. 2021;21(3):139-140.
55. Creaton J. Addressing the mental health crisis. Nat Rev Cancer.
2021;21(1):1-2.
56. Balkwill FR. Cells are Us - combining research and public
engagement. Nat Rev Cancer. 2021;21(5):277-278.
57. Pramesh CS, Badwe RA. Cancer Management in India during Covid-19. N
Engl J Med 2020;382:e61.
58. Martinez JA, Miller RH, Martinez RA. Patient Questions Surrounding
Mask Use for Prevention of COVID-19 and Physician Answers from an
Evidence-Based Perspective: a Narrative Review. J Gen Intern Med
2021;36:2739-44.
59. Tung EL, De Marchis EH, Gottlieb LM, Lindau ST, Pantell MS.
Patient Experiences with Screening and Assistance for Social Isolation
in Primary Care Settings. J Gen Intern Med 2021;36:1951-7.
60. Wenger NS, Stanton AL, Baxter-King R, Sepucha K, Vavreck L, Naeim A.
The Impact of COVID-19 on Routine Medical Care and Cancer Screening. J
Gen Intern Med 2022; :1-7.
61. Méndez R, et al. Short-term neuropsychiatric outcomes and quality of
life in COVID-19 survivors. J Intern Med 2021;290:621-31.
62. Hu CS, Tkebuchava T. New “P” in Medical Model. Chin Med J (Engl)
2016;129: 492-3.
63. Hu CS. Intervention of RT-ABCDEF for cancer. Croat Med J
2019;60:55-7.
64. Hu C. Grants supporting research in China. Eur Heart J
2018;39:2342-4.
65. Majumder D, et al. Olive Oil Consumption can Prevent
Non-communicable Diseases and COVID-19: A Review. Curr Pharm Biotechnol
2022;23:261-75.
66. Guasch-Ferré M, et al. Consumption of Olive Oil and Risk of Total
and Cause-Specific Mortality Among U.S. Adults. J Am Coll Cardiol
2022;79:101-12.
67. Kim G, et al. Ultrasound controlled mechanophore activation in
hydrogels for cancer therapy. Proc Natl Acad Sci U S A
2022;119:e2109791119.
68. Newman LA, Winn RA, Carethers JM. Similarities in Risk
for COVID-19 and Cancer Disparities. Clin Cancer Res. 2021;27(1):24-27.
69. Baffert KA, Darbas T, Lebrun-Ly V, et al. Quality of Life of
Patients With Cancer During the COVID-19 Pandemic. In Vivo.
2021;35(1):663-670.
70. Forner D, Murnaghan S, Porter G, et al. Psychosocial Distress in
Adult Patients Awaiting Cancer Surgery during the COVID-19 Pandemic.
Curr Oncol. 2021;28(3):1867-1878.
71. Datta GD, Lauzon M, Salvy SJ, et al. Cancer Screening Practices
Among Healthcare Workers During the COVID-19 Pandemic. Front Public
Health. 2022;10:801805.
72. McCormack V, Aggarwal A. Early cancer diagnosis: reaching targets
across whole populations amidst setbacks. Br J Cancer.
2021;124(7):1181-1182.
73. Perrone AM, Dondi G, Giunchi S, et al. COVID-19 free oncologic
surgical hub: The experience of reallocation of a gynecologic oncology
unit during pandemic outbreak. Gynecol Oncol. 2021;161(1):89-96.
74. Molanouri Shamsi M, Vahed A, Hekmatikar AA, Suzuki K. Combined
Effects of Exercise Training and Nutritional Supplementation
in Cancer Patients in the Context of the COVID-19: A Perspective Study.
Front Nutr. 2022;9:847215.
75. Papandreou P, Gioxari A, Nimee F, Skouroliakou M. Application of
Clinical Decision Support System to Assist Breast Cancer Patients
with Lifestyle Modifications during the COVID-19 Pandemic: A Randomised
Controlled Trial. Nutrients. 2021;13(6):2115.
76. Drijver AJ, Reijneveld JC, Wesselman LMP, Klein M. A
Web-Based Lifestyle Intervention Aimed at Improving Cognition in
Patients With Cancer Returning to Work in an Outpatient Setting:
Protocol for a Randomized Controlled Trial. JMIR Res Protoc.
2021;10(4):e22670.
77. Pekmezi DW, Crane TE, Oster RA, et al. Rationale and Methods for a
Randomized Controlled Trial of a Dyadic, Web-Based, Weight Loss
Intervention among Cancer Survivors and Partners: The DUET Study.
Nutrients. 2021;13(10):3472.
78. Blair CK, Adsul P, Guest DD, et al. Southwest Harvest for Health: An
Adapted Mentored Vegetable Gardening Intervention for Cancer Survivors.
Nutrients. 2021;13(7):2319.
79.
http://paper.people.com.cn/rmrbhwb/html/2022-01/17/content_25898848.htm
80. Müller NF, et al. Viral genomes reveal patterns of
the SARS-CoV-2 outbreak in Washington State. Sci Transl Med
2021;13:eabf0202.
81. Chakraborty S, et al. Early non-neutralizing, afucosylated antibody
responses are associated with COVID-19 severity. Sci Transl Med
2022;14:eabm7853.
82. Hu CS, Wu QH, Hu DY. Cardiovascular, diabetes, and cancer strips:
evidences, mechanisms, and classifications. J Thorac Dis.
2014;6(9):1319-1328.
83. Hu C, Tkebuchava T, Wu Q, Hu D. How Far is between Cancer and
Health? Iran J Public Health. 2019;48(5):974-976.
84. Hu C, Wu Q. Health: a dream from reality to the future. Front Med.
2016;10(2):233-5.
85. Hu C, Tkebuchava T. Health in All Laws: A better strategy for global
health. J Evid Based Med. 2022;15(1):10-14.